Canbiola, Inc. (OTC PINK: CANB) Announces Manufacturing and Distribution License Agreement with Hudilab Inc., dba Endless Relief of Colorado

Hicksville, New York - (NewMediaWire) - June 13, 2018 - Canbiola is proud to announce a Distribution and Licensing Agreement with Hudilab Inc., dba Endless Relief of Colorado. This new agreement will add to our continuing effort to grow the company’s revenue and product and service offerings. Endless Relief has developed and owns the Mobius Therapy Cannabidiol-Infused product line that delivers a specialized CBD formulation as transdermal medication delivered on its own or in conjunction with Transcutaneous Electrical Nerve Stimulation Therapy (TENS). The agreement calls for Canbiola to manufacture and to jointly market Endless Relief’s Mobius Therapy products.

“This new relationship expands our expertise in everything CBD, it will also broaden our product and service offerings,” stated Marco Alfonsi, Canbiola CEO.

“Mobius Therapy is a breakthrough helping relieve many types of pain. The combination of the widely accepted pain relief and anti-inflammatory benefits of CBD with the proven medical benefits of TENS, Mobius Therapy provides a first of its kind ‘Pain Relief System’. The synergistic combination of the CBD and TENS provided by Mobius Therapy is an effective alternative to analgesics and opioid drugs for many people,”  stated Franklin Horwich, the CEO of Endless Relief.

TENS is commonly used by doctors and physical therapists to relieve many types of pain. It is effective in the treatment of both acute pain (e.g. after surgery) as well as chronic pain (e.g. back pain). TENS uses electrical energy which is sent in various patterns to electrode pads which are placed on the skin. The electrical signals are transmitted through the skin and directly to the nerves in the painful area. Hence the name Transcutaneous (meaning through the skin) Electrical Nerve Stimulation or TENS for short.

Mobius Therapy combines CBD extract and TENS to block the pain signals that are sent from effected nerves so that they never reach the brain. By interrupting the delivery of these pain messages, Mobius Therapy provides a new level of non-opioid pain relief. In addition to controlling pain, this type of treatment has been shown to reduce inflammation, muscle spasms and to improve circulation in the treated area.

Mobius Therapy can be effectively used for relief of pain associated with a wide variety of conditions including, back pain caused by failed back surgery, degenerative spine issues or disc problems, nerve pain, cancer-related pain, migraines, sleep disturbances, inflammation and acute injury. Whether you are an athlete, a weekend warrior or just someone who works hard or plays hard, Mobius Therapy can relieve pain, muscle stiffness and soreness without opioids. Mobius Therapy can often reduce the use of pain relievers, including opioid drugs, after surgery. Mobius Therapy is compatible with and often used in conjunction with other forms of treatment such as exercise, massage, physiotherapy, biofeedback, and/or spinal manipulation.

The agreement with Canbiola Inc. will deliver the Mobius Therapy and the Canbiola product line to a larger and more diverse customer base.

About Hudilab Inc., dba Endless Relief

Endless Relief invented the Mobius Therapy ‘Pain Relief System’. Mobius Therapy is a combination of medicinal-grade CBD and TENS technology.

Our CBD products are scientifically formulated and precisely crafted using only the highest quality organic and sustainably farmed ingredients. All products are THC free and lab tested to ensure purity and potency. All other ingredients are USDA certified organic and non-GMO, completely non-synthetic, 100% all-natural, and sustainably produced. In combination with our over-the-counter Class-II Medical Device, Mobius Therapy delivers a new approach to pain relief.

About Canbiola, Inc. 
Canbiola, Inc. is a public company trading under symbol CANB.

Canbiola, Inc. is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola is in the process of developing its own line of proprietary products as well as seeking synergistic value through acquisitions and license agreements in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has been legalized for recreational or medical purposes in some form in only a limited number of states. The company’s current products can be found at

The company also owns two technological solutions, Wrapmail (US Patent 8,572,275), which turns traditional email into a powerful marketing and branding tool, as well the Bullseye platform of document management and compliance targeted at broker-dealers, public companies, and governmental agencies providing an all-in-one solution for document management, retention, and compliance.

Forward-Looking Statements

Forward-looking statements and risks and uncertainties Matters discussed in this press release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.

Canbiola Investor Relations
Phone: (516) 595-9544
Follow us on Twitter and Facebook